Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Progress in multiple sclerosis research in the last year.
Receptos provides update on progress of lead product candidate RPC1063
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
Lodonal/LDN
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Magnetic resonance imaging in multiple sclerosis - patients' experiences, information interests and responses to an education programme.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Subclinical CNS Inflammation as Response to a Myelin Antigen in Humanized Mice.
The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
Depakote: No Prescription Cheap Low
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
UVB light attenuates the systemic immune response in CNS autoimmunity.
Tysabri prescribing information
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Pages